Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Therapeutic monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) are established treatments for certain cancers.
• Current EGFR antibodies primarily function through receptor signaling inhibition and antibody-dependent cellular cytotoxicity.
• Complement-dependent cytotoxicity (CDC), a potent antibody-mediated cell-killing mechanism, has been considered inactive for EGFR antibodies.

Purpose of the Study:

• To investigate the potential for complement activation by therapeutic EGFR antibodies.
• To identify combinations of EGFR antibodies that can induce potent complement-dependent cytotoxicity.
• To explore the underlying mechanisms and generalizability of this synergistic effect.

Main Methods:

• Screening of various EGFR antibody combinations for complement activation.
• Assessment of tumor cell lysis induced by synergistic antibody combinations.
• Analysis of antibody-epitope interactions to understand the mechanism of synergy.

Main Results:

• Specific combinations of EGFR antibodies demonstrated potent activation of the complement system via the classic pathway.
• These synergistic combinations led to effective lysis of tumor cells.
• The observed synergy was found to be a general mechanism applicable to combinations of human IgG1 antibodies recognizing distinct, non-overlapping epitopes.

Conclusions:

• Therapeutic EGFR antibodies possess an unexpected capacity for synergistic complement activation.
• Combining specific EGFR antibodies can overcome the previously assumed inactivity of CDC.
• This finding opens avenues for novel therapeutic strategies to enhance the efficacy of EGFR-targeted cancer treatments.